feedback

Course Director

Pascal Chanez, MD, PhD
Pascal Chanez, MD, PhD

Professor, Department of Respiratory Diseases
Aix-Marseille University
Marseille, France

Faculty

Alan Kaplan
Alan Kaplan, MD, CCFP(EM), FCFP

Clinical Lecturer, University of Toronto
Chairperson, Family Physician Airways Group of Canada
Toronto, Ontario

Andrew Menzies-Gow
Andrew Menzies-Gow, BSc, MBBS, PhD, FRCP

Honorary Senior Lecturer, Imperial College London
Consultant Respiratory Physician, Royal Brompton Hospital
London, United Kingdom

Accredited by

Oakstone Publishing, LLC

View Activity Materials

Activity Details

Credit Types:CME
Credit Amount:0.5 Credits
Release Date:2017-Jul-18
Expiration Date:2018-Jul-17
Estimated Time for Completion:30 minutes
Registration Required:No
Cost:Free of charge

Funding Disclosure

This activity is supported by an educational grant from AstraZeneca.

Activity Description and Educational Objectives

In this activity, two asthma experts and a primary care practitioner discuss how to identify patients who may benefit from biologic therapies for their asthma, how to decide which biologic therapy, as well as differences and similarities amongst current and emerging biologics for clinical practice.

Upon completion of this activity, participants should be better able to:

  • Describe how current and emerging biologic therapies target the pathogenesis of severe Th2-mediated asthma
  • Explain how to identify which patients with uncontrolled severe asthma may benefit from biologic therapies, based on symptomatology and specific biomarker
  • Identify opportunities to individualise treatment plans for patients with severe Th2-mediated asthma, based on current and emerging clinical data associated with biologic therapies

Target Audience

This activity has been designed to meet the educational needs of pulmonologists, allergists, primary care physicians, and other clinicians involved in the management of severe asthma.

Faculty Disclosure Statement / Conflict of Interest Policy

Oakstone Publishing, LLC has assessed conflict of interest with its faculty, authors, editors, and any individuals who were in a position to control the content of this CME activity. Any identified relevant conflicts of interest were resolved for fair balance and scientific objectivity of studies utilized in this activity. Oakstone Publishing’s planners, medical reviewers, and editorial staff disclose no relevant financial relationships with commercial interests.

Course Director and Moderator

Pascal Chanez, MD, PhD
Professor, Department of Respiratory Diseases
Aix-Marseille University
Marseille, France

Pascal Chanez, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant for Almirall Ltd; AstraZeneca Plc; Boehringer Ingelheim GmbH; Chiesi Farmaceutici S.p.A.; GlaxoSmithKline Plc; Johnson & Johnson Services, Inc.; Merck Sharp & Dohme Corp.; Novartis Pharmaceuticals; sanofi-aventis U.S. LLC; SNCF; and Teva Pharmaceutical Industries Ltd.
Grant/Research Support from ALK; Almirall Ltd; Aix-Marseille Université; AstraZeneca Plc; Boehringer Ingelheim GmbH; Boston Scientific Corporation; Centocor Biotechnology; Chiesi Farmaceutici S.p.A.; GlaxoSmithKline Plc; Novartis Pharmaceuticals; and Teva Pharmaceutical Industries Ltd.
Advisory Board for Almirall Ltd; AstraZeneca Plc; Boehringer Ingelheim GmbH; Centocor Biotechnology; Chiesi Farmaceutici S.p.A.; GlaxoSmithKline Plc; Johnson & Johnson Services, Inc.; Novartis Pharmaceuticals; sanofi-aventis U.S. LLC; Schering-Plough Corporation; and Teva Pharmaceutical Industries Ltd.

Faculty

Alan Kaplan, MD, CCFP(EM), FCFP
Clinical Lecturer, University of Toronto
Chairperson, Family Physician Airways Group of Canada
Toronto, Ontario

Alan Kaplan, MD, CCFP(EM), FCFP, has a financial interest/relationship or affiliation in the form of:
Consultant for Johnson and Johnson Inc. and Purdue Pharma Canada.
Grant/Research Support from Novartis Pharmaceuticals Canada Inc.
Speakers Bureau participant with AstraZeneca; Boehringer Ingelheim.; Grifols Canada.; Johnson and Johnson Inc.; MEDA Pharmaceuticals Ltd.; Merck Frosst Canada Inc; Myelin Repair Foundation; Novartis Pharmaceuticals Canada; Novo Nordisk Canada Inc; Pfizer Inc.; Purdue Pharma Canada; Sanofi Canada; Teva Canada Limited; and Trudell Medical International.
Honoraria from AstraZeneca; Boehringer Ingelheim.; GlaxoSmithKline Plc; Grifols Canada Ltd.; Johnson and Johnson Inc.; MEDA Pharmaceuticals Ltd.; Merck Frosst Canada Inc; Myelin Repair Foundation; Novartis Pharmaceuticals Canada Inc; Novo Nordisk Canada Inc; Pfizer Inc.; Purdue Pharma Canada; Sanofi Canada; Teva Canada Limited; The Myelin Repair Foundation; and Trudell Medical International.
Advisory Board for AstraZeneca Plc; Boehringer Ingelheim (Canada) Ltd.; GlaxoSmithKline Plc; MEDA Pharmaceuticals Ltd.; Myelin Repair Foundation; Novo Nordisk Canada Inc; Novartis Pharmaceuticals Canada Inc; Pfizer Inc.; Purdue Pharma Canada; and Teva Canada Limited.

Andrew Menzies-Gow, BSc, MBBS, PhD, FRCP
Honorary Senior Lecturer, Imperial College London
Consultant Respiratory Physician, Royal Brompton Hospital
London, United Kingdom

Andrew Menzies-Gow, BSc, MBBS, PhD, FRCP, has a financial interest/relationship or affiliation in the form of:
Consultant for AstraZeneca Plc and Vectura Group Plc.
Grant/Research Support from AstraZeneca Plc; Boehringer Ingelheim GmbH; F. Hoffmann-La Roche Ltd; and Glaxo SmithKline Plc.
Speakers Bureau participant with AstraZeneca Plc; Boehringer Ingelheim GmbH; Novartis Pharmaceuticals; Teva Pharmaceutical Industries Ltd; and Vectura Group Plc.
Honoraria from AstraZeneca Plc; Boehringer Ingelheim GmbH; F. Hoffmann-La Roche Ltd; Glaxo SmithKline Plc; Mundipharma International Ltd; Novartis Pharmaceuticals; and Teva Pharmaceutical Industries Ltd.
Advisory Board for AstraZeneca Plc; Boehringer Ingelheim GmbH; F. Hoffmann-La Roche Ltd; Glaxo SmithKline Plc; Mundipharma International Ltd; Novartis Pharmaceuticals; and Teva Pharmaceutical Industries Ltd.

PeerVoice Medical Director

Christy Rohani, PhD, has no financial interests/relationships or affiliations in relation to this activity.

Disclosure of Unlabelled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labelled for use in certain jurisdictions. Faculty members have been advised to disclose to the audience any reference to an unlabelled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our materials. No responsibility is taken for errors or omissions in our materials.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Oakstone Publishing, LLC and PeerVoice. Oakstone Publishing, LLC is accredited by the ACCME to provide continuing medical education for physicians.

Oakstone Publishing, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

This CME activity is jointly provided by Oakstone Publishing, LLC and PeerVoice.

Requirements for Successful Completion

To receive credit, participants must complete the activity, the post-test, and the evaluation form prior to the expiration date noted below. There are no pre-requisites and there is no fee to participate in this activity or to receive credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form. Consult your professional licensing board for information about your eligibility to claim credit for participation in this educational activity. A minimum performance level of 70% is needed.

Media: Enduring Material
Release and Expiration Dates: July 18, 2017-July 17, 2018
Time to Complete: 30 minutes

Disclaimer

The participants of this educational activity have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerVoice or any of its supporters.

For technical assistance, please contact us.

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.